<DOC>
	<DOCNO>NCT01364181</DOCNO>
	<brief_summary>Pulmonary hypertension ( PH ) serious complication COPD associate short survival , frequent exacerbation , increase use health resource . There effective pharmacological treatment COPD-associated PH . Therefore , investigator want evaluate effect udenafil , phosphodiesterase- 5 ( PDE-5 ) inhibitor , exercise capacity severe COPD patient .</brief_summary>
	<brief_title>The Impact Udenafil Exercise Capacity Severe Chronic Obstructive Pulmonary Disease ( COPD ) Patients</brief_title>
	<detailed_description>Study design - prospective , single arm , open-label study - Udenafil 50mg qd po 8 week</detailed_description>
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Lung Diseases , Obstructive</mesh_term>
	<mesh_term>Pulmonary Disease , Chronic Obstructive</mesh_term>
	<mesh_term>Hypertension , Pulmonary</mesh_term>
	<mesh_term>Dyspnea</mesh_term>
	<mesh_term>Phosphodiesterase 5 Inhibitors</mesh_term>
	<mesh_term>Udenafil</mesh_term>
	<criteria>Severe COPD show postbronchodilator forced expiratory volume 1 second ( FEV1 ) less 50 % predict value Acute exacerbation within 4 week study entry Coronary heart disease History adverse event PDE5 inhibitor</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>May 2011</verification_date>
	<keyword>Udenafil</keyword>
	<keyword>Chronic obstructive pulmonary disease</keyword>
	<keyword>pulmonary hypertension</keyword>
	<keyword>Phosphodiesterase 5 inhibitor</keyword>
	<keyword>Exercise</keyword>
	<keyword>Dyspnea</keyword>
</DOC>